Back to search
FDAFDA · Food and drugs·Recall number D-0160-2017

Indiomin MB URINARY ANTISEPTIC, ANTISPASMODIC Capsules, Each capsule contains: Methenamine 120 mg, Monobasic Sodium Phosphate 40.8 mg, Methylene Blue, 10 mg; Hyoscyamine Sulfate, 0.12 mg, 100 count, Rx only, Manufactured for: BUREL PHARMACEUTICALS, NDC 35573-315-10

Published December 7, 2016 · Recall initiated: October 24, 2016

Summary

FDA records drug Class II recall D-0160-2017, published December 7, 2016 and initiated October 24, 2016. Recalling firm: Burel Pharmaceuticals Inc; Status: Terminated; Reported quantity: 795 bottles; Lot: LOT # 29401501, EXP 10/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Burel Pharmaceuticals Inc
Distributor
Nationwide
Lot
LOT # 29401501, EXP 10/17
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Indiomin MB URINARY ANTISEPTIC, ANTISPASMODIC Capsules, Each capsule contains: Methenamine 120 mg, Monobasic Sodium Phosphate 40.8 mg, Methylene Blue, 10 mg; Hyoscyamine Sulfate, 0.12 mg, 100 count, Rx only, Manufactured for: BUREL PHARMACEUTICALS, NDC 35573-315-10 recalled?

Yes. FDA published recall D-0160-2017 on December 7, 2016. Reported hazard: CGMP Deviations; deficiencies at the manufacturer may result in assay or content uniformity failures

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail